{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"P1101"},{"type":"USBrandName","name":"Besremi"},{"type":"Synonym","name":"PEG-P-IFN-alpha-2b"},{"type":"Synonym","name":"PEG-proline-interferon Alfa-2b"},{"type":"Synonym","name":"PEG-P-IFN-alfa-2b"},{"type":"CodeName","name":"AOP2014"},{"type":"CASRegistryName","name":"1335098-50-4"},{"type":"CodeName","name":"P-1101"}],"definition":{"html":"A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b), in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon administration of ropeginterferon alfa-2b, IFN-a2b targets and binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with IFN-specific response elements (ISREs). Their protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a single positional isomer which further increases its stability and half-life.","text":"A long-acting formulation of recombinant interferon alpha subtype 2b (IFN-a2b), in which IFN-a2b is coupled, via proline, to polyethylene glycol (PEG), with antiviral, immunomodulating and antineoplastic activities. Upon administration of ropeginterferon alfa-2b, IFN-a2b targets and binds to specific IFN cell-surface receptors. This activates IFN-mediated signal transduction pathways and induces the transcription and translation of genes with IFN-specific response elements (ISREs). Their protein products mediate antiviral, antiproliferative, anticancer, and immune-modulating effects. The PEG moiety inhibits proteolytic breakdown and clearance of IFN-a2b, which prolongs its half-life, extends the duration of its therapeutic effects and allows less frequent dosing. The proline linker facilitates the synthesis of a single positional isomer which further increases its stability and half-life."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/ropeginterferon-alfa-2b-njft","text":"Ropeginterferon Alfa-2b-njft"},"nciConceptId":"C111892","nciConceptName":"Ropeginterferon Alfa-2B","termId":753252,"name":"ropeginterferon alfa-2B","firstLetter":"r","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"ropeginterferon-alfa-2b"}],"links":null}